Showing 5551-5560 of 9847 results for "".
- Is PIILIF the Precursor to Scarring Alopecias?https://practicaldermatology.com/news/is-piilif-the-precursor-for-scarring-alopecias/2461978/A single root condition called PIILIF (perifollicular infundibulo-isthmic lymphocytic infiltrates and fibrosis) may be a precursor for acne keloidalis nuchae (AKN) and primary cicatricial alopecias, according to a study in
- Are Wealthy People at Higher Risk for Skin Cancer?https://practicaldermatology.com/news/are-wealthy-people-are-more-prone-to-skin-cancer/2461972/Wealthier people are at greater risk for melanoma, according to new research in Cancers. “A higher socio-economic status is known to be associated with more vacations in sunny climates and recreational tanning, which likely ultimately drives melanoma incidence in this pop
- Study Links Gut Microbiome and Eczema in Infancyhttps://practicaldermatology.com/news/study-links-gut-microbiome-and-eczema-in-infancy/2461971/New research has revealed associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota. The study was
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- New Kerecis Medical-Fish-Skin Product Approved by Medicare Administrative Contractorshttps://practicaldermatology.com/news/new-kerecis-medical-fish-skin-product-approved-by-medicare-administrative-contractors/2461961/Multiple leading Medicare Administrative Contractors have approved Kerecis Shield, the new fish-skin wound-treatment product. This means that physicians in private clinics will not need to submit invoices for reimbursement, improving efficiency by eliminating a step in the reimbursement proc
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the&
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree